[
  {
    "ts": "2025-11-21T07:14:06+00:00",
    "headline": "The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade",
    "summary": "Earlier this week, Phillip Frost, CEO and Chairman of OPKO Health, together with Frost Gamma Investments Trust, acquired OPKO Health shares totaling US$737,747, substantially increasing his direct and indirect holdings in the company. This insider activity coincided with Jefferies downgrading OPKO Health from Buy to Hold due to concerns regarding stagnant sales guidance for Ngenla, the firm's growth hormone treatment developed with Pfizer. Let's explore how Phillip Frost's significant...",
    "url": "https://finance.yahoo.com/news/bull-case-opko-health-opk-071406434.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "87d20a7c-cacb-3e91-a883-5b1481c14be5",
      "content": {
        "id": "87d20a7c-cacb-3e91-a883-5b1481c14be5",
        "contentType": "STORY",
        "title": "The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade",
        "description": "",
        "summary": "Earlier this week, Phillip Frost, CEO and Chairman of OPKO Health, together with Frost Gamma Investments Trust, acquired OPKO Health shares totaling US$737,747, substantially increasing his direct and indirect holdings in the company. This insider activity coincided with Jefferies downgrading OPKO Health from Buy to Hold due to concerns regarding stagnant sales guidance for Ngenla, the firm's growth hormone treatment developed with Pfizer. Let's explore how Phillip Frost's significant...",
        "pubDate": "2025-11-21T07:14:06Z",
        "displayTime": "2025-11-21T07:14:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-opko-health-opk-071406434.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-opko-health-opk-071406434.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OPK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T13:00:00+00:00",
    "headline": "This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase",
    "summary": "The drugmaker may not continue to lag the market for much longer.",
    "url": "https://www.fool.com/investing/2025/11/21/this-7-yielding-dividend-stock-is-about-to-enter/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "94a9de7a-4ce4-3f35-8d8a-81fa5c455e4d",
      "content": {
        "id": "94a9de7a-4ce4-3f35-8d8a-81fa5c455e4d",
        "contentType": "STORY",
        "title": "This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase",
        "description": "",
        "summary": "The drugmaker may not continue to lag the market for much longer.",
        "pubDate": "2025-11-21T13:00:00Z",
        "displayTime": "2025-11-21T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/58e2a851f91ddf3fa7436cfb109da81b",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Doctor and patient in a hospital room.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qh7xsLg1i0wtlmLPaJEwCQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/58e2a851f91ddf3fa7436cfb109da81b.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OqAeJoWOLZr5hSBNbRkgEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/58e2a851f91ddf3fa7436cfb109da81b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/21/this-7-yielding-dividend-stock-is-about-to-enter/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/7-yielding-dividend-stock-enter-130000462.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T12:41:00+00:00",
    "headline": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms",
    "summary": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.",
    "url": "https://finance.yahoo.com/news/pfes-acquired-drugs-drive-non-124100204.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "315ef055-ab2e-322b-befd-e292f7e8f8f0",
      "content": {
        "id": "315ef055-ab2e-322b-befd-e292f7e8f8f0",
        "contentType": "STORY",
        "title": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms",
        "description": "",
        "summary": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.",
        "pubDate": "2025-11-21T12:41:00Z",
        "displayTime": "2025-11-21T12:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ffSS19YaoL36xXdlr0Ip4A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mJhhM1.2_VWzkATXxZYL_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfes-acquired-drugs-drive-non-124100204.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfes-acquired-drugs-drive-non-124100204.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T14:34:32+00:00",
    "headline": "The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing",
    "summary": "Watch the Video I began the conversation with Lee by noting how rarely investors stop to consider how dramatically the upper ranks of the stock market have changed. When we looked back twenty five years, the list of dominant companies in the S&P 500 was almost unrecognizable compared with today. What the Top of the ... The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing",
    "url": "https://247wallst.com/investing/2025/11/21/the-great-sp-500-shakeup-leaves-microsoft-and-oracle-the-last-giants-standing/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d2d7b95c-ba11-3bc9-88c0-2f2d6036224f",
      "content": {
        "id": "d2d7b95c-ba11-3bc9-88c0-2f2d6036224f",
        "contentType": "STORY",
        "title": "The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing",
        "description": "",
        "summary": "Watch the Video I began the conversation with Lee by noting how rarely investors stop to consider how dramatically the upper ranks of the stock market have changed. When we looked back twenty five years, the list of dominant companies in the S&P 500 was almost unrecognizable compared with today. What the Top of the ... The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing",
        "pubDate": "2025-11-21T14:34:32Z",
        "displayTime": "2025-11-21T14:34:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/030464a404131febaaee71ce6b2d73ef",
          "originalWidth": 1920,
          "originalHeight": 1080,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sxipV7tUzAca3O.SQc7rbQ--~B/aD0xMDgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/24_7_wall_st__718/030464a404131febaaee71ce6b2d73ef.cf.webp",
              "width": 1920,
              "height": 1080,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pd79GgzGd_mPNE13pKVc9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/030464a404131febaaee71ce6b2d73ef.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/11/21/the-great-sp-500-shakeup-leaves-microsoft-and-oracle-the-last-giants-standing/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/great-p-500-shakeup-leaves-143432774.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "C"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "INTC"
            },
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T14:00:04+00:00",
    "headline": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finance.yahoo.com/news/trending-stock-pfizer-inc-pfe-140004586.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e0851696-2411-3172-aafb-3ab8bd5c91df",
      "content": {
        "id": "e0851696-2411-3172-aafb-3ab8bd5c91df",
        "contentType": "STORY",
        "title": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?",
        "description": "",
        "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
        "pubDate": "2025-11-21T14:00:04Z",
        "displayTime": "2025-11-21T14:00:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2",
          "originalWidth": 900,
          "originalHeight": 741,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EYdBVn9rFNc9AepqcsmXXg--~B/aD03NDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2.cf.webp",
              "width": 900,
              "height": 741,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UC8YVzs0fyygH41RFBV7Qg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/trending-stock-pfizer-inc-pfe-140004586.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T18:24:00+00:00",
    "headline": "U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer",
    "summary": "NEW YORK & TOKYO, November 21, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy",
    "url": "https://finance.yahoo.com/news/u-fda-approves-padcev-plus-182400214.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f095d1d6-7581-3b01-ac81-991fd4fb19ee",
      "content": {
        "id": "f095d1d6-7581-3b01-ac81-991fd4fb19ee",
        "contentType": "STORY",
        "title": "U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer",
        "description": "",
        "summary": "NEW YORK & TOKYO, November 21, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy",
        "pubDate": "2025-11-21T18:24:00Z",
        "displayTime": "2025-11-21T18:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/097b44bf9ed164bc0a32d896c9d679e8",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l6R2jwkl4M2nxQ8GZUGFig--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/097b44bf9ed164bc0a32d896c9d679e8.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pg_TK7O64GMzW2agkFsYsw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/097b44bf9ed164bc0a32d896c9d679e8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-fda-approves-padcev-plus-182400214.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-fda-approves-padcev-plus-182400214.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "4503.T"
            },
            {
              "symbol": "ALPMF"
            },
            {
              "symbol": "ALPMY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T19:37:45+00:00",
    "headline": "Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.",
    "summary": "Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.",
    "url": "https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f9b725a0-70ec-3d7c-b6ad-57019bb16362",
      "content": {
        "id": "f9b725a0-70ec-3d7c-b6ad-57019bb16362",
        "contentType": "STORY",
        "title": "Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.",
        "description": "",
        "summary": "Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.",
        "pubDate": "2025-11-21T19:37:45Z",
        "displayTime": "2025-11-21T19:37:45Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f9b725a0-70ec-3d7c-b6ad-57019bb16362/fighting-cancer-with-smart.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/237de1ebdaae3c2cd271d4caaa7f01d0",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jpyb2VHadwLpdm8jAVYfhQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/237de1ebdaae3c2cd271d4caaa7f01d0.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SeUW7GFT6kjZe0KkGlgiZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/237de1ebdaae3c2cd271d4caaa7f01d0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "GNMSF"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T21:12:00+00:00",
    "headline": "FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer",
    "summary": "RAHWAY, N.J., November 21, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who a",
    "url": "https://finance.yahoo.com/news/fda-approves-keytruda-pembrolizumab-keytruda-211200017.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "7400cf76-ba42-3387-8143-899c26361398",
      "content": {
        "id": "7400cf76-ba42-3387-8143-899c26361398",
        "contentType": "STORY",
        "title": "FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer",
        "description": "",
        "summary": "RAHWAY, N.J., November 21, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who a",
        "pubDate": "2025-11-21T21:12:00Z",
        "displayTime": "2025-11-21T21:12:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/caca6a1d58c4191b3538079d087fcb12",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WbJ0ZrFvCjNqyIv0pyNTKg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/caca6a1d58c4191b3538079d087fcb12.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eX9j1hcSMl4WttTeVVtAWg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/caca6a1d58c4191b3538079d087fcb12.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-keytruda-pembrolizumab-keytruda-211200017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-keytruda-pembrolizumab-keytruda-211200017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T20:45:25+00:00",
    "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
    "summary": "Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-higher-204525142.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c42c5ad5-50de-30e7-bc08-ad252cd0e534",
      "content": {
        "id": "c42c5ad5-50de-30e7-bc08-ad252cd0e534",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Higher Late Afternoon",
        "description": "",
        "summary": "Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health",
        "pubDate": "2025-11-21T20:45:25Z",
        "displayTime": "2025-11-21T20:45:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-higher-204525142.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-higher-204525142.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T18:30:02+00:00",
    "headline": "3 Simple Options Strategies to Act on Thursday’s Unusual Activity Now",
    "summary": "Market volatility has ratcheted up in recent days. The S&P 500 was on course for its worst week in months before Friday’s open. These three strategies rely on Thursday’s unusual options activity for investors wanting to keep things simple.",
    "url": "https://www.barchart.com/story/news/36257891/3-simple-options-strategies-to-act-on-thursdays-unusual-activity-now",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "9474d576-417a-3a18-89a3-dab0f634b3ce",
      "content": {
        "id": "9474d576-417a-3a18-89a3-dab0f634b3ce",
        "contentType": "STORY",
        "title": "3 Simple Options Strategies to Act on Thursday’s Unusual Activity Now",
        "description": "",
        "summary": "Market volatility has ratcheted up in recent days. The S&P 500 was on course for its worst week in months before Friday’s open. These three strategies rely on Thursday’s unusual options activity for investors wanting to keep things simple.",
        "pubDate": "2025-11-21T18:30:02Z",
        "displayTime": "2025-11-21T18:30:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/0463803824d2bdd44d6ecc31e493d64d",
          "originalWidth": 1600,
          "originalHeight": 1000,
          "caption": "Options button on browser by Pashalgnatov via iStock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/88kVvVAL2jo51D2uDsm0kQ--~B/aD0xMDAwO3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/0463803824d2bdd44d6ecc31e493d64d.cf.webp",
              "width": 1600,
              "height": 1000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r7QnZrIR4x3H100aupIlwQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/0463803824d2bdd44d6ecc31e493d64d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36257891/3-simple-options-strategies-to-act-on-thursdays-unusual-activity-now",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-simple-options-strategies-act-183002241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": null,
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T23:55:53+00:00",
    "headline": "Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.",
    "url": "https://finance.yahoo.com/news/pfizer-unitedhealth-viatris-addus-homecare-235553721.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "5833fbd2-7e76-3afb-8afe-b42299e52753",
      "content": {
        "id": "5833fbd2-7e76-3afb-8afe-b42299e52753",
        "contentType": "STORY",
        "title": "Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know",
        "description": "",
        "summary": "A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.",
        "pubDate": "2025-11-21T23:55:53Z",
        "displayTime": "2025-11-21T23:55:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PFE Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o3tZoPUio75qXATbHoc_Hg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5rZqD7vIoFGnsFYAS_Ztw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-unitedhealth-viatris-addus-homecare-235553721.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-unitedhealth-viatris-addus-homecare-235553721.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "DGX"
            },
            {
              "symbol": "UNH"
            },
            {
              "symbol": "VTRS"
            },
            {
              "symbol": "ADUS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-21T17:21:56+00:00",
    "headline": "Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts",
    "summary": "(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse",
    "url": "https://finance.yahoo.com/news/lilly-becomes-first-healthcare-firm-163654047.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "f046e9aa-2a09-328a-85ca-8662eea06aa4",
      "content": {
        "id": "f046e9aa-2a09-328a-85ca-8662eea06aa4",
        "contentType": "STORY",
        "title": "Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts",
        "description": "",
        "summary": "(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse",
        "pubDate": "2025-11-21T17:21:56Z",
        "displayTime": "2025-11-21T17:21:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/22a7a40d7e5596194d74c9df87127927",
          "originalWidth": 800,
          "originalHeight": 450,
          "caption": "A drone view shows the Eli Lilly logo on one of the company’s offices after it hit $1 trillion in market value on Friday, becoming the first drugmaker to join the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse, in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dqT1xN1mWQp_OhIQpZt1Vg--~B/aD00NTA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/22a7a40d7e5596194d74c9df87127927.cf.webp",
              "width": 800,
              "height": 450,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wbr_7CYT8drQ_Az1FLR9ww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/22a7a40d7e5596194d74c9df87127927.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-becomes-first-healthcare-firm-163654047.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-becomes-first-healthcare-firm-163654047.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]